Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is overpriced on P/E.
Target Price
The average target price of SLNO is 108 and suggests 146% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell